Patents-Review.com
ClassID:

96957 ⎘

C07K14/53 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Colony-stimulating factor [CSF]

Sub-classes:
Recent Application in this class:
#1
20260033467
2026-02-05

METHODS AND MODELS FOR ASSESSING EFFICACY OF IMMUNOTHERAPIES

 #2
20250304640
2025-10-02

DUAL CSF1-IL-10 CYTOKINE

 #3
20250051798
2025-02-13

RNA CONSTRUCT

 #4
20250041337
2025-02-06

FUSION PROTEIN

 #5
20240228576
2024-07-11

THERAPEUTIC AGENTS

 #6
20240189423
2024-06-13

BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS

 #7
20240141292
2024-05-02

MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY

 #8
20240139345
2024-05-02

NUCLEIC ACID VECTORS AND METHODS OF USE

 #9
20240076348
2024-03-07

THERAPEUTIC AGENTS

 #10
20230374452
2023-11-23

CORONAVIRUS-INFECTIVE CELLS AND METHOD OF PREPARING SAME

 #11
20230226122
2023-07-20

MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS

 #12
20230159602
2023-05-25

ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS

 #13
20220306715
2022-09-29

CHIMERIC PROTEINS IN AUTOIMMUNITY

 #14
20220220441
2022-07-14

RAPID AND DETERMINISTIC GENERATION OF MICROGLIA FROM HUMAN PLURIPOTENT STEM CELLS

 #15
20220144909
2022-05-12

CSF1R-BASED CHIMERIC PROTEINS

 #16
20220031741
2022-02-03

Methods and reagents for modulating macrophage phenotype

 #17
20210403514
2021-12-30

Compositions and methods for treatment of bone associated diseases

 #18
20210101952
2021-04-08

Engineered Optimized Cytokine Compositions

 #19
20210095000
2021-04-01

Therapeutic agents

 #20
20210009951
2021-01-14

Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy

 #21
20210000937
2021-01-07

Parapoxvirus vectors

 #22
20200331981
2020-10-22

Therapeutic agents

 #23
20200277353
2020-09-03

Therapeutic agents

 #24
20200255842
2020-08-13

Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia

 #25
20200181241
2020-06-11

Ultralong complementarity determining regions and uses thereof

 #26
20200123214
2020-04-23

CSF1R-based chimeric proteins

 #27
20190382466
2019-12-19

CSF1R-CD40L chimeric proteins

 #28
20190336544
2019-11-07

Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

 #29
20190290688
2019-09-26

Methods and reagents for modulating macrophage phenotype

 #30
20190248845
2019-08-15

Compositions and methods for treatment of bone associated diseases

 #31
20190169249
2019-06-06

CSF1R-based chimeric proteins

 #32
20190002521
2019-01-03

Therapeutic agents

 #33
20180135062
2018-05-17

Recombinant probiotic bacteria

 #34
20180112193
2018-04-26

CSF1 THERAPEUTICS

 #35
20170002051
2017-01-05

AVIAN COLONY STIMULATING FACTOR 1 RECEPTOR BINDING PROTEINS

 #36
20160280753
2016-09-29

Biologically active proteins having increased in vivo and/or in vitro stability

 #37
20160090615
2016-03-31

Method for producing natively folded proteins in a prokaryotic host

 #38
20150209409
2015-07-30

Uses of IL-12 in hematopoiesis

 #39
20140356326
2014-12-04

BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY

 #40
20140271538
2014-09-18

Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients

 #41
20140086871
2014-03-27

Ultralong complementarity determining regions and uses thereof

 #42
20130323200
2013-12-05

Gelsolin stimulation of blood samples using gold particles

 #43
20120330838
2012-12-27

System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse

 #44
20120258071
2012-10-11

Compositions and methods of use for MGD-CSF in disease treatment

 #45
20120230947
2012-09-13

BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY

 #46
20120220011
2012-08-30

UNSTRUCTURED RECOMBINANT POLYMERS AND USES THEREOF

 #47
20120202245
2012-08-09

Method for producing natively folded proteins in a prokaryotic host

 #48
20120190909
2012-07-26

Uses of IL-12 in hematopoiesis

 #49
20120183495
2012-07-19

Avian colony stimulating factor 1 receptor binding proteins

 #50
20120046240
2012-02-23

Method of Producing Hydroxyalkyl Starch Derivatives

 #51
20110206635
2011-08-25

Uses of IL-12 in hematopoiesis

 #52
20110171687
2011-07-14

Unstructured recombinant polymers and compositions comprising same

 #53
20110142801
2011-06-16

Protease resistant modified IFN beta polypeptides and their use in treating diseases

 #54
20110054152
2011-03-03

Hydroxyalkyl starch derivatives

 #55
20110020266
2011-01-27

G-CSF Conjugates

 #56
20110003384
2011-01-06

Compositions and methods of use for MGD-CSF in disease treatment

 #57
20100317609
2010-12-16

Method of Producing Hydroxyalkyl Starch Derivatives

 #58
20100278778
2010-11-04

Method for bone marrow preservation or recovery

 #59
20100278777
2010-11-04

Method for treating deficiency in hematopoiesis

 #60
20100189682
2010-07-29

Biologically active proteins having increased In Vivo and/or In Vitro stability

 #61
20090131318
2009-05-21

Protease resistant modified erythropoietin polypeptides

 #62
20090123974
2009-05-14

Interferon-β mutants with increased anti-proliferative activity

 #63
20090092982
2009-04-09

Methods and compositions for increasing biological molecule stability

 #64
20090053147
2009-02-26

Protease resistant modified interferon-beta polypeptides

 #65
20090041734
2009-02-12

USE OF CELL IMPLANTS IN BLADDER AND GUT OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF PEPTIDES

 #66
20090036652
2009-02-05

Purification of proteins using preparative reverse phase chromatography (RPC)

 #67
20080274081
2008-11-06

Protease resistant interferon beta mutants

 #68
20080227953
2008-09-18

c-Mpl LIGAND POLYPEPTIDE

 #69
20080194477
2008-08-14

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #70
20080159977
2008-07-03

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #71
20080075672
2008-03-27

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #72
20080039341
2008-02-14

Unstructured recombinant polymers and uses thereof

 #73
20070264277
2007-11-15

Compositions and Methods of Use for Mgd-Csf in Disease Treatment

 #74
20070254838
2007-11-01

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #75
20070224665
2007-09-27

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #76
20070172459
2007-07-26

Protease resistant interferon beta mutants

 #77
20070123696
2007-05-31

G-CSF CONJUGATES

 #78
20070092482
2007-04-26

Conjugates of a G-CSF moiety and a polymer

 #79
20070010660
2007-01-11

G-CSF conjugates

 #80
20070004904
2007-01-04

G-CSF CONJUGATES

 #81
20060286069
2006-12-21

G-CSF conjugates

 #82
20060286068
2006-12-21

G-CSF conjugates

 #83
20060281897
2006-12-14

Potentialization of the activation of high molecular weight prodrugs

 #84
20060276586
2006-12-07

Peg-physiologically active polypeptide homodimer complex having prolonged in vivo half-life and process for the preparation thereof

 #85
20060270829
2006-11-30

G-CSF CONJUGATES

 #86
20060270703
2006-11-30

G-CSF CONJUGATES

 #87
20060246544
2006-11-02

Manufacturing process for the production of peptides grown in insect cell lines

 #88
20060106734
2006-05-18

System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse

 #89
20060025570
2006-02-02

Megakaryocyte stimulating factors

 #90
20060020116
2006-01-26

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

 #91
20060019877
2006-01-26

Hasylated polypeptides

 #92
20050289058
2005-12-29

System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse

 #93
20050277588
2005-12-15

Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses

 #94
20050245471
2005-11-03

Combination products for use in antitumoral treatment

 #95
20050238723
2005-10-27

Method of producing hydroxyalkyl starch derivatives

 #96
20050234230
2005-10-20

Hydroxyalkyl starch derivatives

 #97
20050147587
2005-07-07

G-CSF conjugates

 #98
20050144133
2005-06-30

System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse

 #99
20050136034
2005-06-23

Uses of IL-12 in hematopoiesis

 #100
20050119454
2005-06-02

Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins

 #101
20050095684
2005-05-05

G-CSF conjugates

 #102
20050063946
2005-03-24

Human pluripotent hematopoietic colony stimulating factor, method of production and use

 #103
20050037959
2005-02-17

Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses

 #104
20050027457
2005-02-03

Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins